New Alzheimer's drug donanemab tested in Real-World setting
NCT ID NCT06566170
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 22 times
Summary
This study looks at whether adding the drug donanemab to standard care helps people with early Alzheimer's stay independent longer. About 6,250 participants will be followed for over 5 years in real-world clinics. The goal is to see if donanemab slows the need for daily help or nursing home care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Rehabilitation & Neurological Services
RECRUITINGHuntsville, Alabama, 35805-4046, United States
Contact
Conditions
Explore the condition pages connected to this study.